Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $114.00

Structure Therapeutics (NASDAQ:GPCR) had its price objective hoisted by HC Wainwright from $90.00 to $114.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently commented on the company. BMO Capital Markets restated an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, January 6th. Morgan Stanley upped their price target on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Citizens Jmp dropped their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Stifel Nicolaus boosted their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Finally, Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $107.90.

Structure Therapeutics Stock Up 0.2%

GPCR opened at $63.13 on Monday. The company’s 50-day moving average price is $75.10 and its 200 day moving average price is $47.65. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The firm has a market cap of $4.46 billion, a price-to-earnings ratio of -79.91 and a beta of -1.80.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Research analysts anticipate that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GPCR. Envestnet Asset Management Inc. acquired a new position in shares of Structure Therapeutics during the 2nd quarter valued at $221,000. Assetmark Inc. boosted its stake in Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares in the last quarter. Bank of Montreal Can boosted its stake in Structure Therapeutics by 9.1% during the second quarter. Bank of Montreal Can now owns 58,073 shares of the company’s stock valued at $1,224,000 after buying an additional 4,838 shares in the last quarter. Quinn Opportunity Partners LLC grew its holdings in Structure Therapeutics by 90.9% during the second quarter. Quinn Opportunity Partners LLC now owns 42,000 shares of the company’s stock worth $871,000 after acquiring an additional 20,000 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Structure Therapeutics by 29.1% in the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after acquiring an additional 994 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.